Monday, October 19, 2026

The AI Psych Brief

🔬 Section 1

Psychiatric Research Article

Impact of Cannabis Use on Time to Psychiatric Rehospitalization in Young Adults With Bipolar and Psychotic Disorders: A Survival Analysis

Perino J, Daveluy A, Truong-Bastos A, Miremont F, Fatseas M, Tournier M · Journal of Clinical Psychiatry · September 2026

Bordeaux investigators followed every 18- to 29-year-old admitted full-time for a psychotic or bipolar disorder at their center in 2017 (n = 200), using medical records through May 2023. Excluding alcohol and tobacco, 44% reported current drug use at admission and 37% had a substance use disorder; cannabis dominated, with 43% current users.

Current cannabis use at admission predicted early return: the hazard of psychiatric readmission was 2.8 times higher in the first month after discharge, fell to 1.9 by three months, and was no longer significant by six months.

💡 Why it matters

In a young adult with psychosis or bipolar disorder who is using cannabis, the first 90 days after discharge are when readmission risk concentrates — the window to front-load follow-up, cannabis-focused intervention and family contact. This is a single-center retrospective cohort, so it identifies a high-risk window rather than proving cannabis causes the relapse.

Read the paper → doi:10.4088/JCP.25m16257

📚 Section 2

Landmark Study

Depressive Symptoms and Health-Related Quality of Life: The Heart and Soul Study

Ruo B, Rumsfeld JS, Hlatky MA, Liu H, Browner WS, Whooley MA · JAMA · July 2003

A landmark from *50 Studies Every Psychiatrist Should Know*. The Heart and Soul Study enrolled 1,024 outpatients with stable coronary artery disease in the San Francisco Bay Area and asked a deceptively simple question: what drives how sick a cardiac patient feels — the heart, or the mood?

Twenty percent had depressive symptoms (PHQ ≥10). After adjusting for objective cardiac measures, depressive symptoms were associated with greater symptom burden (OR 1.8), physical limitation (OR 3.1), worse quality of life (OR 3.1), and worse overall health (OR 2.0). Ejection fraction and inducible ischemia were not associated with any of these patient-reported outcomes; only exercise capacity was.

💡 Why it matters

Twenty years on this still holds: in chronic medical illness, how a patient feels tracks mood more closely than the organ test — so the PHQ belongs alongside the echo. The cohort later showed that depression's link to cardiac events is largely explained by health behaviors like inactivity and nonadherence, which is why treating depression in heart disease is pursued for function and behavior, not as a direct cardioprotective intervention.

Read the paper → doi:10.1001/jama.290.2.215

💊 Section 3

Psychiatric Fact

Xanomeline-trospium's trospium half is designed to stay out of the brain

Xanomeline is an M1/M4-preferring muscarinic agonist; its antipsychotic effect is thought to come from central M4 modulation of striatal dopamine release — no D2 blockade, hence little EPS or prolactin elevation. But xanomeline alone failed in the 1990s because peripheral muscarinic agonism caused intolerable nausea, vomiting, sweating and salivation.

Trospium is a quaternary amine antimuscarinic that does not meaningfully cross the blood-brain barrier, so it blunts the peripheral cholinergic effects while leaving the central agonism intact. The practical consequences follow from that design: the side-effect profile is anticholinergic at the periphery, so urinary retention, gastric retention and untreated narrow-angle glaucoma are contraindications, and trospium is renally cleared, which makes moderate-to-severe renal impairment a reason for caution. Dose it on an empty stomach per the label and expect GI effects to be front-loaded in the first weeks of titration.

🛋️ Section 4

Psychotherapy Teaching Pearl

Identification with the aggressor: the patient may be showing you what was done to them

Ferenczi, and later Anna Freud, described how a person overwhelmed by an aggressor may survive by becoming like them — anticipating, adopting, and later re-enacting the aggressor's stance. In treatment this often shows up not as content but as role reversal: the patient treats the therapist the way they were once treated — contemptuous, unpredictable, humiliating — and the therapist is left feeling small, confused or frightened. The countertransference is then a sample of the patient's original experience. The technical risk is either retaliating or collapsing; the opportunity is to use the feeling as information and, when the alliance can bear it, name the reversal of roles rather than only the hostility.

🗒️ Vignette

A woman with an abusive, mocking father begins correcting her resident's grammar and laughing at his questions. He feels like a scolded child and catches himself over-preparing for sessions. Rather than defending himself or interpreting her anger, he says: 'I notice I've started to feel like I can't get anything right in here — I wonder if that's a feeling you know well.' She goes quiet, then describes dinners where her father quizzed and ridiculed her. The move names the role reversal from inside his own experience, so it reaches her history without accusing her of cruelty.